Among US individuals with HCV, the proportion in the easy-to-treat (non-cirrhotic, non-GT3) bucket is probably about 75%. However, among US individuals with diagnosed HCV, the proportion in the easy-to-treat bucket is lower for two reasons: 1) non-cirrhotic patients have a lower chance of having been diagnosed (as you noted); and 2) a smaller proportion of GT3 patients, compared to other genotypes, has already been treated.
Partially offsetting item #1 is that patients already treated are more likely to be cirrhotic than the proportion of cirrhotic patients in the overall diagnosed pool.
All told, my guess for the number you’re seeking is 60%. However, the more pertinent number may be one that puts advanced fibrosis in the same bucket as cirrhosis, as 'dangerM' is suggesting (#msg-130800480, #msg-130800713), in which case the percentage of diagnosed patients in the easy bucket is considerably lower.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.